Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after primingjeanfrancoismaisonMay 301 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/39672823/
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosishttps://pubmed.ncbi.nlm.nih.gov/40467521/
Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activityhttps://pubmed.ncbi.nlm.nih.gov/40450523/
Comments